Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1328

2.

The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy.

Warshamana-Greene GS, Litz J, Buchdunger E, García-Echeverría C, Hofmann F, Krystal GW.

Clin Cancer Res. 2005 Feb 15;11(4):1563-71.

3.
5.

The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth.

Krystal GW, Honsawek S, Litz J, Buchdunger E.

Clin Cancer Res. 2000 Aug;6(8):3319-26.

6.

Insulin-like growth factor I-mediated protection from rapamycin-induced apoptosis is independent of Ras-Erk1-Erk2 and phosphatidylinositol 3'-kinase-Akt signaling pathways.

Thimmaiah KN, Easton J, Huang S, Veverka KA, Germain GS, Harwood FC, Houghton PJ.

Cancer Res. 2003 Jan 15;63(2):364-74.

7.

Activated c-Met signals through PI3K with dramatic effects on cytoskeletal functions in small cell lung cancer.

Maulik G, Madhiwala P, Brooks S, Ma PC, Kijima T, Tibaldi EV, Schaefer E, Parmar K, Salgia R.

J Cell Mol Med. 2002 Oct-Dec;6(4):539-53.

8.

Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells.

Pfeil K, Eder IE, Putz T, Ramoner R, Culig Z, Ueberall F, Bartsch G, Klocker H.

Prostate. 2004 Feb 15;58(3):259-68.

PMID:
14743465
9.

A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells.

Martelli AM, Tazzari PL, Tabellini G, Bortul R, Billi AM, Manzoli L, Ruggeri A, Conte R, Cocco L.

Leukemia. 2003 Sep;17(9):1794-805.

PMID:
12970779
10.

Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells.

Kijima T, Maulik G, Ma PC, Tibaldi EV, Turner RE, Rollins B, Sattler M, Johnson BE, Salgia R.

Cancer Res. 2002 Nov 1;62(21):6304-11.

11.
12.

Preferential killing of PTEN-null myelomas by PI3K inhibitors through Akt pathway.

Zhang J, Choi Y, Mavromatis B, Lichtenstein A, Li W.

Oncogene. 2003 Sep 18;22(40):6289-95.

PMID:
13679867
15.
17.
18.

Phosphatidylinositol 3-kinases inhibitor LY294002 potentiates the cytotoxic effects of doxorubicin, vincristine, and etoposide in a panel of cancer cell lines.

Badinloo M, Esmaeili-Mahani S.

Fundam Clin Pharmacol. 2014 Aug;28(4):414-22. doi: 10.1111/fcp.12043. Epub 2013 Jul 10.

PMID:
23837575
19.

Mono- or dual-phosphorylation of akt kinase is regulated by distinct receptors that involve the common insulin receptor substrate.

Schnyder B, Lahm H, Pittet M, Schnyder-Candrian S.

J Recept Signal Transduct Res. 2002 Feb-Nov;22(1-4):213-28.

PMID:
12503617
20.

Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance.

Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H.

J Biol Chem. 2001 Mar 30;276(13):9817-24. Epub 2001 Jan 3.

Supplemental Content

Support Center